The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Drugmaker GSK and U.S. biotechnology company AnaptysBio started litigation against one another, with each saying the other party breached a licensing agreement for cancer treatment Jemperli. Tesaro, a ...

Some four years into Jemperli’s commercial life span, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. Tesaro has filed a lawsuit ...

GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal with Flagship Pioneering. Flagship’s Profound Therapeutics and Quotient ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

GlaxoSmithKline is now known simply as GSK. GSK stock trades for 13 times earnings and barely 11 times free cash flow. The pharmaceutical giant pays a 3.3% dividend yield and is growing earnings in ...